13462-79-8

Upstream product

• 87-89-8 D-myo-inositol 
• 6763-47-9 rac-1,2-O-cyclohexylidene-myo-inositol 
• 39110-61-7 3,4,5,6-tetra-O-acetyl-1,2-O-cyclohexylidene-myo-inositol 
• 76690-10-3 1⁽³⁾-O-(2-tetrahydropyranyl)-3⁽¹⁾,4⁽⁶⁾,5,6⁽⁴⁾-tetra-O-acetyl-sn-myoinositol 
• 76690-10-3 2-O-(2-tetrahydropyranyl)-1⁽³⁾,4⁽⁶⁾,5,6⁽⁴⁾-tetra-O-acetyl-sn-myoinositol 
• 4136-18-9 1⁽³⁾,2-di-O-(2-tetrahydropyranyl)-3⁽¹⁾-4⁽⁶⁾,5,6⁽⁴⁾-tetra-O-acetyl-sn-myoinositol 

Downstream Products

• 25348-62-3 Acetic acid (3aR,4R,5S,6S,7R,7aS)-5,6,7-triacetoxy-2-thioxo-hexahydro-benzo[1,3]dioxol-4-yl ester 
• 6931-62-0 (+/-)-1,4,5,6-Tetra-O-acetyl-3-O-mesyl-myo-inosit 
• 29971-56-0 2-O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-1(3),4(6),5,6(4)-tetra-O-acetyl-sn-myo-inositol 
• 80065-86-7 1(3)-O-(β-benzoylpropionyl)-2-O-(2,3,4,6-tetra-O-acetyl-β-D-mannopyranosyl)-3(1),4(6),5,6(4)-tetra-O-acetyl-sn-myoinositol 
• 80065-86-7 1(3)-O-(β-benzoylpropionyl)-2-O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-3(1),4(6),5,6(4)-tetra-O-acetyl-sn-myoinositol 
• 526-87-4 (+/-)-Conduritol B 
• 4381-96-8 (+/-)-(1,3/2,4)-1,2,3,4-tetra-O-acetyl-5-cyclohexene-1,2,3,4-tetrol 
• 6090-95-5 conduritol β-epoxide 
• 5160-25-8 1,3,4,5,6-Penta-O-acetyl-2-O-methansulfonyl-myo-inosit 
• 52389-41-0 1(3),3(1),4(6),5,6(4)-penta-O-acetyl-sn-myoinositol 
• 20021-56-1 DL-(1,3/2,4)-1,2,3,4-Tetra-O-acetylcyclohexanetetrol 
• 6730-18-3 Pentaacetyl-1-azido-1-deoxy-scyllo-inosit 
• 135346-51-9 Acetic acid (1S,2S,5R,6S)-5,6-diacetoxy-2-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-cyclohex-3-enyl ester 
• 135346-53-1 ((1S,4S,5R,6R)-4,5,6-Triacetoxy-cyclohex-2-enyl)-acetic acid 2-thioxo-2H-pyridin-1-yl ester 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyIoidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

SYNTHESIS OF BRANCHED-CHAIN CYCLITOLS USING A PALLADIUM(0)-CATALYZED ALLYLIC COUPLING REACTION

A carbanion derived from Meldrum's acid was used in a palladium(0)-catalysed allylic substitution reaction to prepare stereospecifically branched-chain cyclitols from the symmetrical 1,2,3,4-tetraacetoxycyclohex-5-ene (4).

INVESTIGATIONS IN THE FIELD OF ASYMMETRICALLY SUBSTITUTED MYOINOSITOL DERIVATIVES. XXX. REACTION OF 2,3-DIHYDROPYRAN WITH TETRASUBSTITUTED DERIVATIVES OF MYOINOSITOL

In the reaction of 2,3-dihydropyran with 1(3),4(6),5,6(4)-tetra-O-benzyl- and 1(3),4(6),5,6(4)-tetra-O-acetyl-sn-myoinositols the corresponding mono- and ditetrahydropyranyl ethers are formed.